Side by side
Cagrilintide vs Fat Blaster
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Cagrilintide | Fat Blaster | |
|---|---|---|
| What it is | A long-acting amylin analogue in late-stage trials. It works on a different satiety pathway from the GLP-1 drugs. Which is why it is being developed alongside semaglutide rather than against it. | A marketing name, not a formula. What is in the syringe varies by clinic, and no version of it has been shown to cause weight loss. |
| EvidenceHow much human evidence exists, not how well it works. | Clinical trials | Preclinical |
| Regulatory statusReviewed 2026-08-16 | Not approved anywhere, alone or in combination. In late-stage clinical development as CagriSema, a fixed combination with semaglutide. Anything sold as cagrilintide today is a research chemical produced outside the manufacturing controls that a future approval would rest on. | Not an approved medicine. Sold as a compounded preparation, which means it is mixed by a pharmacy for a specific patient rather than manufactured and reviewed as a product. The FDA does not review compounded preparations for safety or effectiveness before they are sold. |
| Routes | Subcutaneous | Intramuscular |
| Half-life | 180 hours | Not recorded |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $4.40/mg | Not recorded |
| Median per mg | $9.60/mg | Not recorded |
| Vendors with a price | 31 | Not recorded |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Nothing to reconstitute. Compounded preparations carry a beyond-use date rather than a manufacturer's expiry, and it is usually short. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.